Lee Jae-Hoon, Kang Jeonghyun, Baik Seung Hyuk, Lee Kang Young, Lim Beom Jin, Jeon Tae Joo, Ryu Young Hoon, Sohn Seung-Kook
From the Department of Nuclear Medicine (JHL, TJJ, YHR); Department of Surgery (JK, SHB, SKS); Department of Pathology (BJL), Gangnam Severance Hospital, Yonsei University College of Medicine, and Department of Surgery (KYL), Yonsei University College of Medicine, Seoul, South Korea.
Medicine (Baltimore). 2016 Jan;95(1):e2236. doi: 10.1097/MD.0000000000002236.
To evaluate clinical values of clinicopathologic and 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT)-related parameters for prediction of v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation in colorectal cancer (CRC) and to investigate their variability depending on C-reactive protein (CRP) levels. In total, 179 CRC patients who underwent PET/CT scans before curative resection and KRAS mutation evaluation following surgery were enrolled. Maximum standardized uptake value (SUV max), peak standardized uptake value (SUV peak), metabolic tumor volume, and total lesion glycolysis were determined semiquantitatively. Associations between clinicopathologic and PET/CT-related parameters and KRAS expression were analyzed. Elevated CRP (> 6.0 mg/L; n = 47) was associated with higher primary tumor size, higher SUV max, SUV peak, metabolic tumor volume, and total lesion glycolysis, compared with those for the group with a CRP lower than that the cutoff value (< 6.0 mg/L; n = 132). Interestingly, the CRC patients (having CRP < 6.0 mg/L) with KRAS mutations had significantly higher (P < 0.05) SUV max and SUV peak values than the patients expressing wild-type KRAS mutations. Multivariate analysis revealed SUV max and SUV peak to be significantly associated with KRAS mutations (odds ratio = 3.3, P = 0.005, and odds ratio = 3.9, P = 0.004), together with histologic grade and lymph node metastasis. 18F-FDG uptake was significantly higher in CRC patients with KRAS mutations and with normal CRP levels. A severe local inflammation with raised CRP levels, however, might affect accurate 18F-FDG quantification in CRC tumors. Positron emission tomography/computed tomography-related parameters could supplement genomic analysis to determine KRAS expression in CRC; however, care should be exercised to guarantee proper patient selection.
评估临床病理及18F-氟脱氧葡萄糖(18F-FDG)正电子发射断层扫描/计算机断层扫描(PET/CT)相关参数对预测结直肠癌(CRC)中v-Ki-ras2 Kirsten大鼠肉瘤病毒癌基因同源物(KRAS)突变的临床价值,并研究其随C反应蛋白(CRP)水平的变化情况。总共纳入了179例在根治性切除术前接受PET/CT扫描且术后进行KRAS突变评估的CRC患者。半定量测定最大标准化摄取值(SUV max)、峰值标准化摄取值(SUV peak)、代谢肿瘤体积和总病变糖酵解。分析临床病理及PET/CT相关参数与KRAS表达之间的关联。与CRP低于临界值(<6.0 mg/L;n = 132)的组相比,CRP升高(>6.0 mg/L;n = 47)与更大的原发肿瘤大小、更高的SUV max、SUV peak、代谢肿瘤体积和总病变糖酵解相关。有趣的是,KRAS突变的CRC患者(CRP<6.0 mg/L)的SUV max和SUV peak值显著高于表达野生型KRAS突变的患者(P<0.05)。多因素分析显示,SUV max和SUV peak与KRAS突变显著相关(优势比分别为3.3,P = 0.005;优势比为3.9,P = 0.004),同时还与组织学分级和淋巴结转移相关。KRAS突变且CRP水平正常的CRC患者的18F-FDG摄取显著更高。然而,CRP水平升高导致的严重局部炎症可能会影响CRC肿瘤中18F-FDG的准确量化。正电子发射断层扫描/计算机断层扫描相关参数可补充基因组分析以确定CRC中的KRAS表达;然而,应谨慎选择合适的患者。